Reports Q2 revenue $589,897 vs. $726,404 last year. “We continue to set a strong foundation that we believe positions us for success as we advance our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy across various oncology indications where there remains significant unmet need. We continue to work with our partners and believe the data and information will be invaluable as we look to realize the full potential of our DNase platform technology. Looking ahead, we remain focused on building momentum across all fronts and driving development toward an IND and Phase 1 clinical trial,” commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic (XBIO).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XBIO:
- Xenetic Biosciences Reports Improved Financial Performance
- Is XBIO a Buy, Before Earnings?
- Xenetic says PeriNess enters clinical study agreement for DNase Platform
- Xenetic expands collaboration with The Scripps Research Institute
- Xenetic says PeriNess reports Bnei Zion Medical Center commences patient dosing